Johnson & Johnson (JNJ) Stock Price, News & Analysis

Company Overview

Johnson & Johnson (NYSE: JNJ) is a diversified global healthcare company founded in 1886 and headquartered in New Brunswick, New Jersey. Over its more than 135-year history, the company has evolved from a single–product focus on sterile surgical supplies into a broad-based provider of pharmaceuticals, medical devices and consumer health products. Johnson & Johnson’s long-standing commitment to research and innovation has driven the development of numerous groundbreaking treatments and technologies, solidifying its reputation as a leader in healthcare.

The company operates through three primary business segments. Its Pharmaceutical segment focuses on therapeutic areas such as immunology, oncology, neuroscience, cardiovascular and metabolic diseases, and infectious diseases. In the Medical Devices segment, Johnson & Johnson designs and manufactures products for orthopedics, surgery, interventional solutions and vision care. The Consumer Health segment develops and markets well-known over-the-counter products in categories that include baby care, oral care, wound care, women’s health and skincare.

Johnson & Johnson maintains a global presence, with operations spanning more than 60 countries and products sold in virtually every national market. The company invests heavily in research and development, operating multiple innovation centers and collaboration hubs around the world to advance new medical discoveries. Its extensive supply chain network and manufacturing facilities ensure timely delivery of products to hospitals, pharmacies and retail outlets.

Leadership at Johnson & Johnson emphasizes both operational excellence and social responsibility. Joaquin Duato was appointed Chairman and Chief Executive Officer in January 2022, bringing more than three decades of experience in roles spanning R&D, commercial operations and global strategy. Under his guidance, the company continues to pursue sustainable growth, strengthen its pipeline of new therapies and devices, and uphold commitments to ethical standards and community health initiatives worldwide.

Key Stats

• Today's Range: $162.30 to $164.70
• 50-Day Range: $146.39 to $164.78
• 52-Week Range: $140.68 to $169.99
• Volume: 11.21 million shs
• Average Volume: 8.16 million shs
• Market Capitalization: $392.28 billion
• P/E Ratio: 18.14
• Dividend Yield: 3.19%
• Price Target: $174.11
• Consensus Rating: Moderate Buy

Johnson & Johnson Stock Analysis - MarketRank™

Johnson & Johnson scored higher than 96% of companies evaluated by MarketBeat, and ranked 56th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Johnson & Johnson has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on 9 buy ratings, 11 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Johnson & Johnson has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.63%

Earnings Growth

Earnings for Johnson & Johnson are expected to grow by 4.63% in the coming year, from $10.58 to $11.07 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Johnson & Johnson is 18.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.49.

Price to Earnings Ratio vs. Sector

The P/E ratio of Johnson & Johnson is 18.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.17.

Price to Earnings Growth Ratio

Johnson & Johnson has a PEG Ratio of 2.12. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Johnson & Johnson has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.66% of the float of Johnson & Johnson has been sold short.

Short Interest Ratio / Days to Cover

Johnson & Johnson has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Johnson & Johnson has recently decreased by 3.12%, indicating that investor sentiment is improving.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Johnson & Johnson pays a meaningful dividend of 3.35%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Johnson & Johnson has been increasing its dividend for 64 years.

Dividend Coverage

The dividend payout ratio of Johnson & Johnson is 57.84%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 46.97% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.9 / 5
• Environmental Score: -1.98

Percentage of Shares Shorted

0.66% of the float of Johnson & Johnson has been sold short.

Short Interest Ratio / Days to Cover

Johnson & Johnson has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Johnson & Johnson has recently decreased by 3.12%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.19

News Sentiment

Johnson & Johnson has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 154 news articles for Johnson & Johnson this week, compared to 74 articles on an average week.

Search Interest

116 people have searched for JNJ on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

Only 31 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is a decrease of -23% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Johnson & Johnson insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.16% of the stock of Johnson & Johnson is held by insiders.

Percentage Held by Institutions

69.55% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

JNJ Stock Analysis - Frequently Asked Questions

How have JNJ shares performed this year?

Johnson & Johnson's stock was trading at $144.62 at the beginning of the year. Since then, JNJ shares have increased by 13.2% and is now trading at $163.7630.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) released its quarterly earnings data on Wednesday, July, 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company's quarterly revenue was up 5.8% on a year-over-year basis.
Read the conference call transcript.

Does Johnson & Johnson have any subsidiaries?

Johnson & Johnson subsidiaries include Momenta Pharmaceuticals, TARIS Biomedical, Verb Surgical, Auris Health, Ci:z Holdings, Zarbee's Naturals, Orthotaxy, and more.

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's top institutional investors include Assenagon Asset Management S.A. (0.17%), Kingstone Capital Partners Texas LLC (0.10%), PineStone Asset Management Inc. (0.09%) and Swedbank AB (0.08%). Insiders that own company stock include & Johnson Johnson, Jennifer L Taubert, Peter Fasolo, William Hait, Kathryn E Wengel, Ashley Mcevoy, Thibaut Mongon, Joseph J Wolk, Robert J Decker, Timothy Schmid, James D Swanson and Mark A Weinberger.
View institutional ownership trends.

How do I buy shares of Johnson & Johnson?

Shares of JNJ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Johnson & Johnson investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), UnitedHealth Group (UNH), Gilead Sciences (GILD), Corning (GLW), NextEra Energy (NEE) and Devon Energy (DVN).

Company Calendar

• Record date for 6/10 Dividend: 5/27/2025
• Ex-Dividend for 6/10 Dividend: 5/27/2025
• Dividend Payable: 6/10/2025
• Last Earnings: 7/16/2025
• Today: 7/17/2025
• Record date for 9/9 Dividend: 8/26/2025
• Dividend Payable: 9/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Large Cap Pharma
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:JNJ
• CIK: 200406
• Web: www.jnj.com
• Phone: (732) 524-0400
• Fax: 732-214-0332
• Employees: 138,100
• Year Founded: 1886

Price Target and Rating

• Average Price Target for Johnson & Johnson: $173.50
• High Price Target: $215.00
• Low Price Target: $150.00
• Potential Upside/Downside: +6.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.99
• Trailing P/E Ratio: 18.18
• Forward P/E Ratio: 15.45
• P/E Growth: 2.12
• Net Income: $14.07 billion
• Net Margins: 24.42%
• Pretax Margin: 29.78%
• Return on Equity: 33.46%
• Return on Assets: 13.30%

Debt

• Debt-to-Equity Ratio: 0.49
• Current Ratio: 1.26
• Quick Ratio: 1.03

Sales & Book Value

• Annual Sales: $88.82 billion
• Price / Sales: 4.43
• Cash Flow: $13.82 per share
• Price / Cash Flow: 11.83
• Book Value: $29.69 per share
• Price / Book: 5.51

Miscellaneous

• Outstanding Shares: 2,406,070,000
• Free Float: 2,402,223,000
• Market Cap: $393.35 billion
• Optionable: Optionable
• Beta: 0.41